$ALDX
Aldeyra Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021002456 Filed on October 28, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.563M $2.547M $2.260M
YoY Change 2.51% 12.69% -20.42%
% of Gross Profit
Research & Development $12.84M $12.89M $6.134M
YoY Change 82.67% 110.23% -62.19%
% of Gross Profit
Depreciation & Amortization $61.27K $68.35K $80.00K
YoY Change -138.29% -14.56% 300.0%
% of Gross Profit
Operating Expenses $15.40M $12.89M $6.134M
YoY Change 61.47% 110.23% -62.19%
Operating Profit -$15.44M -$8.389M
YoY Change 84.06% -55.88%
Interest Expense -$350.3K $413.1K $489.2K
YoY Change -27.02% -15.55% 1577.95%
% of Operating Profit
Other Income/Expense, Net -$353.8K -$484.0K
YoY Change -26.9% -260.7%
Pretax Income -$15.75M -$15.79M -$8.873M
YoY Change 33.85% 78.01% -52.59%
Income Tax
% Of Pretax Income
Net Earnings -$15.75M -$15.79M -$8.873M
YoY Change 39.54% 78.01% -52.59%
Net Earnings / Revenue
Basic Earnings Per Share -$0.27
Diluted Earnings Per Share -$271.2K -$272.2K -$234.7K
COMMON SHARES
Basic Shares Outstanding 58.09M 57.86M
Diluted Shares Outstanding 58.02M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $229.8M $241.4M $86.20M
YoY Change 195.14% 180.01% 13.17%
Cash & Equivalents $229.8M $241.4M $86.18M
Short-Term Investments $0.00 $0.00 $0.00
Other Short-Term Assets $2.962M $5.403M $2.000M
YoY Change -43.04% 170.16% 150.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $232.8M $246.8M $88.19M
YoY Change 180.22% 179.81% 14.51%
LONG-TERM ASSETS
Property, Plant & Equipment $32.49K $39.61K $79.46K
YoY Change -45.79% -50.15% -53.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $384.4K $445.6K $131.7K
YoY Change 31.07% 238.49% -68.7%
TOTAL ASSETS
Total Short-Term Assets $232.8M $246.8M $88.19M
Total Long-Term Assets $384.4K $445.6K $131.7K
Total Assets $233.1M $247.2M $88.32M
YoY Change 179.7% 179.9% 14.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.020M $467.9K $123.9K
YoY Change 167.19% 277.67% -78.35%
Accrued Expenses $10.52M $11.25M $4.019M
YoY Change 29.36% 180.0% -64.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $2.300M
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $11.77M $11.94M $6.500M
YoY Change -5.13% 83.73% -46.35%
LONG-TERM LIABILITIES
Long-Term Debt $15.50M $15.42M $12.69M
YoY Change 35.59% 21.49% -11.77%
Other Long-Term Liabilities $125.2K $184.6K
YoY Change
Total Long-Term Liabilities $15.50M $15.42M $12.69M
YoY Change 35.59% 21.49% -11.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.77M $11.94M $6.500M
Total Long-Term Liabilities $15.50M $15.42M $12.69M
Total Liabilities $27.40M $27.55M $19.20M
YoY Change 14.92% 43.48% -27.72%
SHAREHOLDERS EQUITY
Retained Earnings -$294.7M -$278.9M -$225.6M
YoY Change 24.39% 23.63% 21.17%
Common Stock $500.4M $498.6M
YoY Change 68.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $205.7M $219.7M $69.17M
YoY Change
Total Liabilities & Shareholders Equity $233.1M $247.2M $88.32M
YoY Change 179.7% 179.9% 14.05%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$15.75M -$15.79M -$8.873M
YoY Change 39.54% 78.01% -52.59%
Depreciation, Depletion And Amortization $61.27K $68.35K $80.00K
YoY Change -138.29% -14.56% 300.0%
Cash From Operating Activities -$11.58M -$8.434M -$6.240M
YoY Change 39.32% 35.16% -25.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $5.500M
YoY Change -100.0% -3.0%
Cash From Investing Activities $0.00 $0.00 $5.500M
YoY Change -100.0% -3.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 63.78K 26.22M
YoY Change -99.76% 76.68%
NET CHANGE
Cash From Operating Activities -11.58M -8.434M -6.240M
Cash From Investing Activities 0.000 0.000 5.500M
Cash From Financing Activities 0.000 63.78K 26.22M
Net Change In Cash -11.58M -8.370M 25.48M
YoY Change 39.32% -132.85% 109.02%
FREE CASH FLOW
Cash From Operating Activities -$11.58M -$8.434M -$6.240M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$11.58M -$8.434M -$6.240M
YoY Change 39.32% 35.16% -25.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001341235
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36332
dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
761-4904
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38667491
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
58045
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ALDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58092105
CY2021Q3 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
116368688
CY2020Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
52858311
CY2021Q3 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
125000000
CY2020Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
25000000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5403261
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5200957
CY2021Q3 us-gaap Assets Current
AssetsCurrent
246771949
CY2020Q4 us-gaap Assets Current
AssetsCurrent
83059268
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
406014
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233310
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39607
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59925
CY2021Q3 us-gaap Assets
Assets
247217570
CY2020Q4 us-gaap Assets
Assets
83352503
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
467932
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
381638
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11252075
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8134765
CY2021Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2020Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
3659776
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
222158
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
233310
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11942165
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12409489
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
184599
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15420904
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11434456
CY2021Q3 us-gaap Liabilities
Liabilities
27547668
CY2020Q4 us-gaap Liabilities
Liabilities
23843945
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58045432
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58045432
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38667491
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
38667
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
498549312
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
296385619
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278937455
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-236915728
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
219669902
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59508558
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
247217570
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83352503
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12894344
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6133580
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32095132
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17653058
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2546807
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2255617
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8720161
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7480461
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15441151
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8389197
us-gaap Operating Income Loss
OperatingIncomeLoss
-40815293
us-gaap Operating Income Loss
OperatingIncomeLoss
-25133519
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
59306
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5215
us-gaap Investment Income Interest
InvestmentIncomeInterest
122732
us-gaap Investment Income Interest
InvestmentIncomeInterest
287025
CY2021Q3 us-gaap Interest Expense
InterestExpense
413110
CY2020Q3 us-gaap Interest Expense
InterestExpense
489191
us-gaap Interest Expense
InterestExpense
1329166
us-gaap Interest Expense
InterestExpense
1415055
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-353804
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-483976
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1206434
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1128030
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15794955
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8873173
us-gaap Net Income Loss
NetIncomeLoss
-42021727
us-gaap Net Income Loss
NetIncomeLoss
-26261549
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58019099
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37796946
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52688846
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32395217
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15794955
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8873173
us-gaap Net Income Loss
NetIncomeLoss
-42021727
us-gaap Net Income Loss
NetIncomeLoss
-26261549
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4754
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5866
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4754
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5866
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15794955
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8877927
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42021727
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26267415
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59508558
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5186689
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
189811611
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4623251
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
61529
aldx Net Loss
NetLoss
-42021727
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
219669902
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
48082317
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5453520
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40716543
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1058516
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
126966
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5866
aldx Net Loss
NetLoss
-26261549
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
69170447
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
233679945
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1721134
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12124
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
51654
CY2021Q3 aldx Net Loss
NetLoss
-15794955
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
219669902
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
52789666
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1757479
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22446055
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
998097
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
57077
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4754
CY2020Q3 aldx Net Loss
NetLoss
-8873173
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
69170447
us-gaap Profit Loss
ProfitLoss
-42021727
us-gaap Profit Loss
ProfitLoss
-26261549
us-gaap Share Based Compensation
ShareBasedCompensation
6123554
us-gaap Share Based Compensation
ShareBasedCompensation
5453520
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
326672
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
424516
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
91231
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
202909
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
217806
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
202304
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
212823
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
86294
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-684402
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4506394
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-8022095
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30978208
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29176258
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7806
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
0
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
5776090
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
34800000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7806
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29023910
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
189811611
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40716543
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4623251
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1058516
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
61529
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
126966
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
194496391
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41902025
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
163510377
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41749677
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77858311
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44425830
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
241368688
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86175507
us-gaap Interest Paid Net
InterestPaidNet
1011000
us-gaap Interest Paid Net
InterestPaidNet
1042708
CY2020Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
25000000
CY2020Q4 us-gaap Cash
Cash
23494920
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
29363391
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. NATURE OF BUSINESS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the “Company” or “Aldeyra”), a Delaware corporation, is a clinical-stage biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s principal activities to date include raising capital and research and development activities.</span>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company’s management evaluates its estimates and assumptions on an ongoing basis. Management’s most significant estimates in the Company’s consolidated financial statements include, but are not limited to, estimates related to clinical trial accruals, estimates related to prepaid and accrued research and development costs, acquired in-process research and development (“IPR&amp;D”) expense, contingent liabilities, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5110798
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6008140
CY2021Q3 us-gaap Cash
Cash
111966754
CY2021Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4401934
CY2021Q3 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
125000000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
241368688
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77858311
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2021Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
4532903
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
4793794
CY2021Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
870358
CY2020Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
407163
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5403261
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5200957
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2078896
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1323138
CY2021Q3 aldx Accrued Contingent Consideration Payable In Stock Current
AccruedContingentConsiderationPayableInStockCurrent
0
CY2020Q4 aldx Accrued Contingent Consideration Payable In Stock Current
AccruedContingentConsiderationPayableInStockCurrent
2500000
CY2021Q3 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
8644036
CY2021Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2020Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
3659776
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15420904
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11434456
CY2020Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3944094
CY2021Q3 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
529143
CY2020Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
367533
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11252075
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8134765
CY2021Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2020Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2021Q3 aldx End Of Term Charge
EndOfTermCharge
651139
CY2020Q4 aldx End Of Term Charge
EndOfTermCharge
445464
CY2021Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
230235
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
351232
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
316396
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.23
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4562870
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M1D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11998176
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2976765
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
16042500
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
16042500
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1418337
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1757479
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6123554
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5453520
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4608311
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
905169
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.60
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
634214
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M4D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9144100
CY2021Q3 us-gaap Share Price
SharePrice
8.78
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
400000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
441835
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
35078
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
406757
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
222158
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
184599
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
406757
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
441835
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
60782
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
252477
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
128576
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0

Files In Submission

Name View Source Status
0000950170-21-002456-index-headers.html Edgar Link pending
0000950170-21-002456-index.html Edgar Link pending
0000950170-21-002456.txt Edgar Link pending
0000950170-21-002456-xbrl.zip Edgar Link pending
aldx-20210930.htm Edgar Link pending
aldx-20210930.xsd Edgar Link pending
aldx-20210930_cal.xml Edgar Link unprocessable
aldx-20210930_def.xml Edgar Link unprocessable
aldx-20210930_htm.xml Edgar Link completed
aldx-20210930_lab.xml Edgar Link unprocessable
aldx-20210930_pre.xml Edgar Link unprocessable
aldx-ex10_1.htm Edgar Link pending
aldx-ex31_1.htm Edgar Link pending
aldx-ex31_2.htm Edgar Link pending
aldx-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending